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To the editor,
I read with great interest the recent article by Rao and Go regarding new treatment 
options for the management of constipation in the elderly.1 In this article, alvi-
mopan was described as having been “recently…introduced for the treatment of 
opioid-induced constipation”. Furthermore, alvimopan was included in a treatment 
algorithm for   management of opioid-induced chronic constipation in the elderly 
(see Figure 1 in Rao and Go).1 Additionally, other “potential uses” for peripherally 
acting mu-opioid receptor antagonists (including alvimopan) were identified by the 
authors and included treatment of “opioid-related nausea and vomiting, urinary reten-
tion, pruritus or   post-operative ileus”. This characterization of alvimopan requires 
further clarification.
Alvimopan was approved by the US Food and Drug Administration (FDA) in 
2008 for the acceleration of gastrointestinal recovery following partial small or large 
bowel resection with primary anastomosis.2 Alvimopan has not been approved for 
any other indication, such as treatment of opioid-induced constipation. Importantly, 
the Warnings and Precautions section of the label describes the potential adverse 
effects that may be associated with administration of alvimopan 12 mg to patients 
recently exposed to opioids. Furthermore, alvimopan is approved only for short-term, 
in-hospital use, and hospitals dispensing alvimopan must register in and meet all 
of the requirements of the Entereg® Access Support and Education (E.A.S.E.™) 
Program.3
It is important that your readers understand these facts about alvimopan use in 
light of the information provided by Rao and Go.1
Disclosure
Lee Techner, DPM, is the Vice President of Medical Affairs and Pharmacovigilance/
Drug Safety at Adolor Corporation, the company that developed and is comarketing 
Entereg® (alvimopan).
References
1.  Rao SSC, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin 
Interv Aging. 2010;5:163–171.Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts 
Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.






2.  Adolor Corporation. Entereg® (alvimopan) Capsules. Prescribing 
Information. Available at: http://www.entereg.com/images/documents/
prescribing-information.pdf. Accessed 2010 Aug 30.
3.  Adolor Corporation. Entereg (alvimopan) Capsules. Entereg® E.A.S.E.™ 
  Program. Available at: http://www.entereg.com/content/e_a_s_e_pro-
gram/. Accessed 2010 Aug 30.